Neurológia pre prax 2/2018
Monoklonální protilátky v léčbě roztroušené sklerózy
Monoclonal antibodies have become a great challenge in treating Multiple Sclerosis Progress in developing new monoclonal antibodies allows us to affect pathological immune processes on many different levels. For treating MS, we now have available monoclonal antibodies capable of influencing the lymphocytes migration or inducing their depletion. Also, the development of new humanized and human antibodies caused significant improvement of their safety profile. Currently there are four types of monoclonal antibodies available in Europe for treating MS: natalizumab, alemtuzumab, daclizumab and ocrelizumab. The last one has also shown effectivity on suppressing progression of primary progressive form of MS.
Keywords: monoclonal antibodies, multiple sclerosis, natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab












